Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

PURPOSE: CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. MATERIALS AND METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Do-Youn, Kim, Tae-Min, Han, Sae-Won, Shin, Dong-Yeop, Lee, Yun Gyoo, Lee, Keun-Wook, Kim, Jee Hyun, Kim, Tae-You, Jang, In-Jin, Lee, Jong-Seok, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720091/
https://www.ncbi.nlm.nih.gov/pubmed/25715767
http://dx.doi.org/10.4143/crt.2014.258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720091/
https://www.ncbi.nlm.nih.gov/pubmed/25715767
http://dx.doi.org/10.4143/crt.2014.258

Ejemplares similares